After "Healthy China" rose to a national strategy, China's medical and health industry has also entered the fast lane.
At a recent roundtable discussion on the "Health Chinese" series of the 2022 National Two Sessions, Zeng Yu, founder and managing partner of MSA Capital, said that in recent years, a series of revolutionary technological breakthroughs and major scientific discoveries have emerged in gene editing, stem cells and regenerative medicine, brain science, protein structure prediction, single-cell sequencing and other fields, "these subversive advances will provide an accelerator for industrialization research and development in China's medical and health field." ”
Zeng Yu believes that the advent of innovative therapies and innovative drugs will not only contribute to human health, but also promote China's biomedical industry to reach the world's cutting-edge level.
Yu Zeng, founder and managing partner of MSA Capital.
Heyu Capital has been involved in the early investment of the medical track for many years, and when talking about the experience of original scientific research technology transformation and industrial application, Zeng Yu mentioned that he has been looking for pioneers of "original" scientific research in the academic community.
"At present, Heyu Capital focuses on cutting-edge science with an international perspective, and accurately captures early high-quality project investment opportunities with 'in-depth research + professionalism + top scientist resources' sniper style." Heyu Capital focuses on the research and development of real innovative drugs, and is the real original innovation of Chinese. "We feel that to do something that is internationally leading, long-term and valuable is an expression of our values for investing in the pharmaceutical sector, and it is also our firm confidence in China's biomedical industry." ”
In Zeng Yu's view, Shao Feng, an academician of the Chinese Academy of Sciences and deputy director of the Beijing Institute of Life Sciences, is the pioneer of the "original" scientific research she has been looking for in the academic community.
Shao Feng, academician of the Chinese Academy of Sciences and deputy director of the Beijing Institute of Life Sciences.
Shao Feng graduated from the Department of Technical Physics of Peking University in 1996, obtained a master's degree from the Institute of Biophysics of the Chinese Academy of Sciences in 1999, and a doctorate degree from the Department of Biochemistry of the University of Michigan in 2003. In December 2015, at the age of 43, Shao Feng was elected an academician of the Chinese Academy of Sciences, the youngest academician in China at the time. Shao Feng is also the winner of the 2019 Future Science Awards - Life Science Award.
Feng Shao made important contributions in the field of natural immunity and cytokewal death: identified multiple intracellular immune receptors against bacteria, including the recognition of caspase-11 of LPS; further discovered and elucidated the molecular mechanism of inflammation bodies and caspase protein inducing coke death by shearing activation of Gasdermin D (GSDMD), providing new targets for drug development for sepsis and inflammatory diseases, and the identification of membrane punching proteins of the Gasdermin family also redefined coke death. It opens up new directions for cell death and immunity research.
Zeng Yu mentioned that at that time, she saw that Shao Feng's pioneering achievements in the field of cytochromia would have high clinical value and application prospects. Zeng Yu believes that it is a great waste to let scientific research results with great application potential lie in papers or stay in the laboratory, so shao feng is encouraged to start a business.
At the beginning of 2021, Pyrotech Therapeutics was officially established, and Shao Feng was appointed as the co-founder. Based on Shao Feng's leading original scientific discoveries in the field of natural immunity and cytochromia, the company is committed to developing small molecule drugs with completely new mechanisms in the field of inflammation and oncology to meet currently unmet clinical needs.
Academician Shao Feng on the left, Zeng Yu on the left.
Previously, in July 2021, a reporter from the surging news (www.thepaper.cn) went to yanming biology's research and development center in Beijing's Zhongguancun Life Science Park, which was put into use on the same day. Shao Feng said on the same day, "China has reached a time when it needs real original innovation. China's innovative pharmaceutical companies should dare to challenge difficult problems and dare to tackle them. "At the same time, he believes that now is the best time for China's new drug research and development, thanks to the tilt of the national strategy, the favorable medical reform policy, the development of the professional talent team and the construction of the platform, and there is sufficient financial support." We believe that we have the ability and resources to make original innovative drugs that belong to China. ”
Zeng Yu also said that the "Next Big Thing" he believes in is the original innovative First-in-Class innovative drug.
In terms of industrial development and ecological construction, Zeng Yu also pointed out that the domestic policy environment and capital environment to encourage innovation have made medical and health science and technology innovation a hot area for venture capital. She believes that "In China, For Global" is becoming a bright spot in China's healthcare technology innovation, global companies are beginning to buy innovative drugs and other innovative medical technology intellectual property from China, and down payment transactions of hundreds of millions of dollars have begun to appear.
Previously, Heyu Capital has successfully invested in a series of biomedical enterprises such as BGI Gene, Yidu Technology, Nuofuxi Gene, Yanming Bio, Danxu Bio, Muhua Bio, Cadeny Medical, Diying Bio, Monroe Bio, Zhuo Kai Bio, Zhiyun Health, Anxuyuan, Andu Bio, etc. In 2022, Heyu Capital also established the first biomedical RMB fund.